ナロキソン

ナロキソン 化学構造式
465-65-6
CAS番号.
465-65-6
化学名:
ナロキソン
别名:
(4R)-6,10aβ-ジヒドロキシ-11-アリル-4α,5-エポキシ-10β,4aβ-(エピミノエタノ)-1,2,3,4,4a,9,10,10a-オクタヒドロフェナントレン-3-オン;(-)-ナロキソン;4,5α-エポキシ-17-アリル-3,14-ジヒドロキシモルフィナン-6-オン;ナロキソン;17-アリル-4,5α-エポキシ-3,14-ジヒドロキシモルフィナン-6-オン;(5α)-4,5-エポキシ-3,14-ジヒドロキシ-17-(2-プロペニル)モルフィナン-6-オン;(1S,5R,13R,17S)-10,17-ジヒドロキシ-4-(プロパ-2-エン-1-イル)-12-オキサ-4-アザペンタシクロ[9.6.1.01,13.05,17.07,18]オクタデカ-7,9,11(18)-トリエン-14-オン
英語名:
Naloxone
英語别名:
Naloxone impurity;C07252;NALOXONE;NSC 70413;l-naloxone;Naloxone API;-bcd)furanone;Naloxone Base;,5-bcd)furanone;Naloxone (125 mg)
CBNumber:
CB5728727
化学式:
C19H21NO4
分子量:
327.37
MOL File:
465-65-6.mol

ナロキソン 物理性質

融点 :
184° (Lewenstein), 177-178° (Sankyo Co.)
比旋光度 :
D20 -194.5° (c = 0.93 in CHCl3)
沸点 :
465.27°C (rough estimate)
比重(密度) :
1.2223 (rough estimate)
屈折率 :
1.5000 (estimate)
闪点 :
9℃
貯蔵温度 :
2-8°C
溶解性:
クロロホルム(微量、加熱、超音波処理)、DMSO(微量)、メタノール(微量)、
外見 :
個体
酸解離定数(Pka):
pKa 7.94/7.82(H2O,t =20/37,I<0.01) (Uncertain)
色:
ホワイトからオフホワイト
InChIKey:
UZHSEJADLWPNLE-GRGSLBFTSA-N
EPAの化学物質情報:
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5.alpha.)- (465-65-6)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  F,T
Rフレーズ  11-23/24/25-39/23/24/25
Sフレーズ  7-16-36/37-45
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  3
HSコード  2939190000
有毒物質データの 465-65-6(Hazardous Substances Data)
毒性 An opiate antagonist devoid of agonist activity except for mild, specific effects at very high doses. Naloxone displays a high affinity for the μ-opioid receptor, a lesser affinity for the kopioid receptor and has some affinity for δ-opioid receptor subtypes. Naloxone produces a rapid and profound reversal of the effects of opioid administration (e.g., 1 mg, i.v., blocks the effects of 25 mg of heroin). Naloxone also antagonizes the analgesia induced by placebo, acupuncture, and stress, and in animals the hypotension due to hypovolemia or spinal cord injury. Naloxone has a short half-life (about 1 h in plasma) and is not administered orally because of rapid, “first-pass” metabolism.
絵表示(GHS) GHS hazard pictograms
注意喚起語 警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H302 飲み込むと有害 急性毒性、経口 4 警告 GHS hazard pictograms P264, P270, P301+P312, P330, P501
注意書き
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。
P270 この製品を使用する時に、飲食または喫煙をしないこ と。
P301+P312 飲み込んだ場合:気分が悪い時は医師に連絡する こと。
P501 内容物/容器を...に廃棄すること。

ナロキソン 価格 もっと(4)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01USP1453005 ナロキソン
Naloxone
465-65-6 125mg ¥59000 2018-12-26 購入
Sigma-Aldrich Japan N-004 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
Naloxone solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
465-65-6 1ml ¥5640 2024-03-01 購入
Sigma-Aldrich Japan 1453005 United States Pharmacopeia (USP) Reference Standard
Naloxone United States Pharmacopeia (USP) Reference Standard
465-65-6 200MG ¥58200 2024-03-01 購入
富士フイルム和光純薬株式会社(wako) W01USP1453005 ナロキソン
Naloxone
465-65-6 200mg ¥78300 2024-03-01 購入

ナロキソン 化学特性,用途語,生産方法

効能

麻薬拮抗剤, 呼吸促進薬, オピオイド受容体拮抗薬

説明

It is worth mentioning that N-allylic substitution in a number of morphine derivatives, as a rule, leads to antagonistic properties. Naloxone is a few times stronger than nalorphine as an antagonist. It blocks opiate receptors. It eliminates central and peripheral action of opioids, including respiratory depression. Naloxone is used upon overdose of narcotic analgesics.

使用

Naloxone is a specific opioid antagonist. Narcotic antagonist.

定義

ChEBI: A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an all l group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.

生物学の機能

Because of its fast onset (minutes), naloxone (Narcan) administered IV is used most frequently for the reversal of opioid overdose. However, it fails to block some side effects of the opioids that are mediated by the δ- receptor, such as hallucinations. The rapid offset of naloxone makes it necessary to administer the drug repeatedly until the opioid agonist has cleared the system to prevent relapse into overdose. The half-life of naloxone in plasma is 1 hour. It is rapidly metabolized via glucuronidation in the liver and cleared by the kidney. Naloxone given orally has a large first-pass effect, which reduces its potency significantly. Often an overshoot will follow the administration of naloxone for overdose. The heart rate and blood pressure of the patient may rise significantly. The overshoot is thought to be due to precipitation of acute withdrawal signs by naloxone. Given alone to nonaddicts, naloxone produces no pharmacological effects.
Naloxone is approved for use in neonates to reverse respiratory depression induced by maternal opioid use. In addition, naloxone has been used to improve circulation in patients in shock, an effect related to blockade of endogenous opioids. Other experimental and less well documented uses for naloxone include reversal of coma in alcohol overdose, appetite suppression, and alleviation of dementia from schizophrenia. Side effects of naloxone are minor.

一般的な説明

Naloxone (Narcan) is a pure antagonist at allopioid receptor subtypes. Structurally, it resembles oxymorphoneexcept that the methyl group on the nitrogen isreplaced by an allyl group. This minor structural change retains high binding affinity to the receptor, but no intrinsicactivity. It is used to reverse the respiratory depressant effectsof opioid overdoses.
Naloxone is administered intravenously with an onset ofaction within 2 minutes. Because it is competing with theopioid for the receptor sites, the dose and frequency of administrationwill depend on the amount and type of narcoticbeing antagonized. Overdoses of long-acting opioids(methadone) may require multiple IV doses of naloxone orcontinuous infusions. Neonates born to opioid-exposedmothers may be given IV naloxone at birth to reverse the effectsof opiates.
Very few metabolism studies on naloxone have beenconducted, although the major metabolite found in the urineis naloxone-3-glucuronide.

ナロキソン 上流と下流の製品情報

原材料

準備製品


ナロキソン 生産企業

Global( 63)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21691 55
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49390 58
Shaanxi Dideu Medichem Co. Ltd
+86-029-89586680 +86-18192503167
1026@dideu.com China 9320 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29220 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471
sales@sarms4muscle.com China 10523 58
LEAP CHEM CO., LTD.
+86-852-30606658
market18@leapchem.com China 24738 58
Shanghai Acmec Biochemical Technology Co., Ltd.
+undefined18621343501
product@acmec-e.com China 33349 58
Aladdin Scientific
+1-833-552-7181
sales@aladdinsci.com United States 57511 58
Chemwill Asia Co.,Ltd. 86-21-51086038
chemwill_asia@126.com CHINA 23931 58

465-65-6(ナロキソン)キーワード:


  • 465-65-6
  • 12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4ah-8,9c-iminoethanophenanthro(4,5
  • 12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4ah-8,9c-iminoethanophenanthro[4,5
  • 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-morphinan-6-on
  • 17-allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one
  • 17-allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
  • 1-n-allyl-14-hydroxynordihydromorphinone
  • 1-n-allyl-7,8-dihydro-14-hydroxynormorphinone
  • 4,5-alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)-morphinan-6-on
  • 5-epoxy-3,14-dihydroxy-17-(2-propenyl)-(5alpha)-morphinan-6-on
  • -bcd)furanone
  • -bcd]furan-5(6h)-one
  • l-n-allyl-14-hydroxynordihydromorphinone
  • l-n-allyl-7,8-dihydro-14-hydroxynormorphinone
  • l-naloxone
  • n-allyl-noroxymorphone
  • 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one
  • 9: PN: WO03037310 FIGURE: 4 claimed sequence
  • Morphinan-6-one, 17-allyl-4,5a-epoxy-3,14-dihydroxy- (8CI)
  • Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5a)- (9CI)
  • Normorphinone, N-allyl-7,8-dihydro-14-hydroxy- (7CI)
  • NSC 70413
  • (5alpha)-3,14-Dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one
  • (4R)-6,10aβ-Dihydroxy-11-allyl-4α,5-epoxy-10β,4aβ-(epiminoethano)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-3-one
  • 17-Allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
  • C07252
  • Naloxone (125 mg)
  • Methanol (test Naloxone, 1.0 mg/mL)
  • Naloxone Base
  • Morphinan-6-one,4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)-, (5a)-
  • Naloxone solution
  • (4R)-6,10aβ-ジヒドロキシ-11-アリル-4α,5-エポキシ-10β,4aβ-(エピミノエタノ)-1,2,3,4,4a,9,10,10a-オクタヒドロフェナントレン-3-オン
  • (-)-ナロキソン
  • 4,5α-エポキシ-17-アリル-3,14-ジヒドロキシモルフィナン-6-オン
  • ナロキソン
  • 17-アリル-4,5α-エポキシ-3,14-ジヒドロキシモルフィナン-6-オン
  • (5α)-4,5-エポキシ-3,14-ジヒドロキシ-17-(2-プロペニル)モルフィナン-6-オン
  • (1S,5R,13R,17S)-10,17-ジヒドロキシ-4-(プロパ-2-エン-1-イル)-12-オキサ-4-アザペンタシクロ[9.6.1.01,13.05,17.07,18]オクタデカ-7,9,11(18)-トリエン-14-オン
  • 呼吸興奮薬
  • 麻薬拮抗薬
Copyright 2017 © ChemicalBook. All rights reserved